-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule

PUBT·08/10/2026 21:07:13
Listen to the news
Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule
  • Lexaria Bioscience received a Nasdaq notice on Aug. 4, 2026, citing failure to regain compliance with the $1 minimum bid rule.
  • Nasdaq warned the stock faces delisting, subject to an appeal hearing that would stay any suspension.
  • A reverse stock split took effect Aug. 3, 2026; shares are trading above $1 under new CUSIP 52886N604.
  • A hearing request was filed with the required fee to keep the listing in place while the company seeks to regain compliance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001302), on August 10, 2026, and is solely responsible for the information contained therein.